Ignyta acquires exclusive rights to Lilly's taladegib oncology program

9 November 2015
mergers-acquisitions-big

US oncology-focused biotech firm Ignyta (Nasdaq: RXDX) says it has acquired exclusive worldwide rights relating to pharma major Eli Lilly’s (NYSE: LLY) taladegib oncology development program in exchange for an upfront payment of $2.0 million in cash and the issuance to Lilly of around 1.2 million shares of Ignyta’s common stock.

Taladegib is a potent, orally bioavailable small-molecule hedgehog/smoothened antagonist that has achieved clinical proof-of-concept and a recommended Phase II dose based on results from prior clinical studies. Ignyta also licensed exclusive worldwide rights to the topical formulation of taladegib, which is a late preclinical program being developed for the potential treatment of patients with superficial and nodular basal cell carcinoma.

Concurrent $30 million equity investment in Ignyta by Lilly

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology